relapsed squamous cell lung cancer
Conditions
Interventions
Nedaplatin(80mg/m2/day) and Docetaxel(60mg/m2/day)on day1, every 3 weeks
Sponsors
Shizuoka Cancer Center, Thoracic Oncology Division
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) histologically or cytologically confirmed squamous cell lung cancer 2) received one prior chemotherapy or chemo-radiotherapy with platinum-based regimen 3) no prior treatment with nedaplatin or docetaxel 4) refractory or relapsed and measurable disease 5) performance status of 0-1 on the Eastern Cooperative Oncology Group scale 6) age from 20 to 74 years 7) adequate organ function 8) written informed consent
Exclusion criteria
Exclusion criteria: 1) interstitial pneumonia or pulmonary fibrosis detectable on CT scan 2) symptomatic brain metastasis 3) steroid treatment 4) massive pleural effusion or pericardial effusion 5) active infection 6) history of active double cancer 7) history of severe drug allergy 8) uncontrollable diabetes mellitus 9) HBs antigen 10) history of pregnancy or lactation 11) history of active psychological disease 12) severe drug allergy for 80 polysorbate content medicine 13) any other medical condition that makes the patient unsuitable for inclusion in the study according to the opinion of the investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| response rate | — |
Secondary
| Measure | Time frame |
|---|---|
| overall survival, progression-free survival, adverse events | — |
Countries
Japan
Contacts
Public ContactHaruyasu Murakami
Shizuoka Cancer Center Shizuoka Cancer Center, Thoracic Oncology Division
Outcome results
None listed